{"id":415635,"date":"2021-01-15T07:33:23","date_gmt":"2021-01-15T12:33:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=415635"},"modified":"2021-01-15T07:33:23","modified_gmt":"2021-01-15T12:33:23","slug":"salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/","title":{"rendered":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, Jan.  15, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pYsq64dKbdjinQ7TqF-91-qJybmmtAIuEU9tiKTJRsGfLcFkK1gSD4jnawmDMI_LFguhUlgqaR3yVNUGZM7u9lIOqdMTZBILHXIS03uvT9E=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Salarius Pharm<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RsKs_4ngTkvUlqIMJTrX-NhVFeUvtVOu7QlyPEFhNUHbfceCElVCeRYoP51_40Vmq1ShQsNgENLvS_fUpUj91FrpoSBugQKkML0-I91f6Rs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">aceuticals, Inc<\/a>. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets\u2019 17th Annual Small &amp; Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform.<\/p>\n<p>Details of the panel discussion are as follows:<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%;vertical-align: top\">\n            <strong>Panel<\/strong>\n          <\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%;vertical-align: top\">Targeted Cancer Therapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Date<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">Tuesday, January 19, 2021<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Time<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">8:35 a.m. ET<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Registration<\/strong>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"https:\/\/www.nobleconference.com\/register\/investor-guest\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.nobleconference.com\/register\/investor-guest<\/a><br \/>\n            \n          <\/td>\n<\/tr>\n<\/table>\n<p>During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, as well as the future outlook for research and drug development in the field.<\/p>\n<p>Salarius is developing seclidemstat, a reversible LSD1 inhibitor that is now being studied in two clinical trials \u2014 one trial in relapsed\/refractory Ewing sarcoma, a rare and deadly pediatric bone and soft tissue cancer, and a second trial in advanced solid tumors (AST). Salarius expects to establish maximum tolerated dose (MTD) in its Ewing sarcoma trial and advance into the dose-expansion phase of the Ewing sarcoma trial in early 2021. Salarius also expects to expand the same trial to include additional select sarcomas that share a similar biology to Ewing sarcoma, also known as Ewing-related sarcomas.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Salarius Pharmaceuticals<\/strong><br \/>\n        <br \/>Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients that need them the most. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1\/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also the recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8bVYH0rfz_vhifSvZiTQYkBGJI69CXPQzamuQZr4o_tZBuRefC3tTxrvUpdS3TyQbLrb2ckHTfUGY8P6rb0hyDVSAI_MRvU01CaKz1OAwC4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">salariuspharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as \u201canticipate,\u201d \u201cpotential,\u201d \u201cprogress,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201caim,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201callow,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cgoal,\u201d \u201cprovide,\u201d \u201cable to,\u201d \u201cposition,\u201d \u201cproject,\u201d \u201cdeveloping,\u201d and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: Salarius\u2019 growth strategy; the value of seclidemstat as a potential treatment for Ewing sarcoma and other cancers; the status and anticipated progress and milestones of Salarius\u2019 clinical trials in advanced solid tumors and Ewing sarcoma; statements related to when and if Salarius will establish maximum tolerated dose in the Ewing sarcoma trial; statements related to when and if Salarius will advance into the dose-expansion phase of the Ewing sarcoma trial; statements related to the expansion of Salarius\u2019 clinical trials to include Ewing-related sarcomas; Salarius\u2019 developing seclidemstat for several cancers with high unmet medical need; Salarius plans to initiate additional clinical trials; the timing, pursuit and successful execution of milestones in any of Salarius\u2019 current or future studies. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the sufficiency of Salarius\u2019 capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius\u2019 business operational needs and to achieve its business objectives and strategy; Salarius\u2019 ability to project future capital needs and cash utilization and timing and accuracy thereof; the ability of Salarius to access the remaining funding available under the CPRIT grant; future clinical trial results and impact of results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius\u2019 intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to raise additional capital; the possibility of unexpected expenses or other uses of Salarius\u2019 cash resources; risks related to the COVID-19 outbreak; and other risks described in Salarius\u2019 filings with the Securities and Exchange Commission, including those discussed in Salarius\u2019 quarterly report on Form 10-Q for the quarter ended September 30, 2020 and in Salarius\u2019 annual report on Form 10-K for the year ended December 31, 2019. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management\u2019s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Tiberend Strategic Advisors, Inc.<br \/>Maureen McEnroe, CFA\/Miriam Miller (Investors)<br \/>(212)\u00a0375-2664\/ 2694\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6STrr9noaAmbu-_9sDRe3PDEzPYHmu6kTu7OGQedWy9k-vPDn9DuSqqY82BSWfrrGIIhCR3IPAkXevWRMpDExxDIPbs6PengoGv0GiXeuw4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmcenroe@tiberend.com<\/a>\/<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N-dV5BusIbn_NKunSMdRQ_RkcGT-ExjLVp2IdyeHNqmQv7eBzjSwn_Uc4N2eDU_jCeHwI3x0TIOlDLw3hyh1Eeoei6C5xN7z-YpAp9L9_w4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmiller@tiberend.com<\/a><\/p>\n<p>Johanna Bennett (Media)<br \/>(212)\u00a0375-2686\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TyH4wdsyVARyQT0WZwsK6MAr1eTdtNcQQH0F9Ezv8WTBQzbeWbbl508tQT9cEiwhCLnCydpFvM7xc3cO2elPocKAckJcDJnFtdDijlslo-s2L1XQ7pUGJAG_PTuck2hmBnGUuANqfZmSx7h_4sPe0-TRXPCBx1h-ELMpoAV37kuDKV4thuHHgY8ktuOxLOUI1KAb2a5bBisAbFTKiE8lBDhazaOPpkQLdBSvQDa5SSRLlnd1eIqGh0S3bg_mn1E-4s3QdhzpBkNGf3aEVYq-IQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jbennett@tiberend.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/35f0699e-7aba-4647-bdd4-f0439dfcb9ba\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets\u2019 17th Annual Small &amp; Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform. Details of the panel discussion are as follows: Panel Targeted Cancer Therapeutics Date Tuesday, January 19, 2021 Time 8:35 a.m. ET Registration https:\/\/www.nobleconference.com\/register\/investor-guest During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-415635","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets\u2019 17th Annual Small &amp; Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform. Details of the panel discussion are as follows: Panel Targeted Cancer Therapeutics Date Tuesday, January 19, 2021 Time 8:35 a.m. ET Registration https:\/\/www.nobleconference.com\/register\/investor-guest During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, &hellip; Continue reading &quot;Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-15T12:33:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference\",\"datePublished\":\"2021-01-15T12:33:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/\"},\"wordCount\":953,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/\",\"name\":\"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\",\"datePublished\":\"2021-01-15T12:33:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk","og_description":"HOUSTON, Jan. 15, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that Daniela Y. Santiesteban, Ph.D., Director of Research and Business Development at Salarius Pharmaceuticals, has been invited to participate in a panel discussion during Noble Capital Markets\u2019 17th Annual Small &amp; Microcap Investor Conference (NobleCon17). The conference is taking place January 19-21, 2021 over a virtual platform. Details of the panel discussion are as follows: Panel Targeted Cancer Therapeutics Date Tuesday, January 19, 2021 Time 8:35 a.m. ET Registration https:\/\/www.nobleconference.com\/register\/investor-guest During the event, Dr. Santiesteban and other panel members will discuss the current status of targeted cancer therapies, &hellip; Continue reading \"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-15T12:33:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference","datePublished":"2021-01-15T12:33:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/"},"wordCount":953,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/","name":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=","datePublished":"2021-01-15T12:33:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyNjQzNSMzOTIwNjg0IzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-announces-dr-daniela-santiesteban-to-participate-in-panel-discussion-on-targeted-cancer-therapies-during-virtual-noblecon17-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals Announces Dr. Daniela Santiesteban to Participate in Panel Discussion on Targeted Cancer Therapies During Virtual NobleCon17 Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=415635"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/415635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=415635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=415635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=415635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}